全文获取类型
收费全文 | 191篇 |
免费 | 5篇 |
国内免费 | 6篇 |
专业分类
儿科学 | 2篇 |
基础医学 | 15篇 |
临床医学 | 6篇 |
内科学 | 49篇 |
特种医学 | 9篇 |
外科学 | 106篇 |
综合类 | 3篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 1篇 |
肿瘤学 | 9篇 |
出版年
2022年 | 1篇 |
2021年 | 1篇 |
2020年 | 3篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2016年 | 1篇 |
2015年 | 3篇 |
2014年 | 2篇 |
2013年 | 3篇 |
2012年 | 5篇 |
2011年 | 3篇 |
2010年 | 8篇 |
2009年 | 5篇 |
2008年 | 12篇 |
2007年 | 15篇 |
2006年 | 27篇 |
2005年 | 17篇 |
2004年 | 15篇 |
2003年 | 18篇 |
2002年 | 10篇 |
2001年 | 14篇 |
2000年 | 8篇 |
1999年 | 2篇 |
1998年 | 3篇 |
1997年 | 4篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 4篇 |
1989年 | 4篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有202条查询结果,搜索用时 15 毫秒
1.
Zentrale Gallengangskarzinome 总被引:1,自引:0,他引:1
Prof. Dr. H. Lang G. M. Kaiser T. Zöpf G. C. Sotiropoulos A. Frilling M. Malagó C. E. Broelsch 《Der Chirurg》2006,77(4):325-334
Surgical resection provides the only chance of cure for patients suffering from hilar cholangiocarcinoma. Due to the central anatomic localization within the liver hilum, established guidelines of oncologic surgery are difficult to apply. Resection of the hilar bifurcation alone or in combination with limited hepatic resection can be performed with low morbidity and low mortality but shows a high rate of local tumor recurrence. Usually, extended resection is required to achieve adequate safety margins. Right trisectionectomy complies best with the basic rules of oncologic surgery while allowing the maximum safety margin. The 5-year survival rates reported after right trisectionectomy range between 20% and 40% and reach 59% in selected patients. The increasing experience with living donor transplantation and recent advances in neoadjuvant tumor therapy may lead to renewed discussion of liver transplantation in hilar cholangiocarcinoma. 相似文献
2.
Timothy M. Pawlik Ana Luiza Gleisner Luca Vigano David A. Kooby Todd W. Bauer Andrea Frilling Reid B. Adams Charles A. Staley Eduardo N. Trindade Richard D. Schulick Michael A. Choti Lorenzo Capussotti 《Journal of gastrointestinal surgery》2007,11(11):1478-1487
Re-resection for gallbladder carcinoma incidentally discovered after cholecystectomy is routinely advocated. However, the
incidence of finding additional disease at the time of re-resection remains poorly defined. Between 1984 and 2006, 115 patients
underwent re-resection at six major hepatobiliary centers for gallbladder carcinoma incidentally discovered during cholecystectomy.
Data on clinicopathologic factors, operative details, TNM tumor stage, and outcome were collected and analyzed. Data on the
incidence and location of residual/additional carcinoma discovered at the time of re-resection were also recorded. On pathologic
analysis, T stage was T1 7.8%, T2 67.0%, and T3 25.2%. The median time from cholecystectomy to re-resection was 52 days. At
the time of re-resection, hepatic surgery most often consisted of formal segmentectomy (64.9%). Patients underwent lymphadenectomy
(LND) (50.5%) or LND + common bile duct resection (43.3%). The median number of lymph nodes harvested was 3 and did not differ
between LND alone (n = 3) vs LND + common duct resection (n = 3) (P = 0.35). Pathology from the re-resection specimen noted residual/additional disease in 46.4% of patients. Of those patients
staged as T1, T2, or T3, 0, 10.4, and 36.4%, respectively, had residual disease within the liver (P = 0.01). T stage was also associated with the risk of metastasis to locoregional lymph nodes (lymph node metastasis: T1 12.5%;
T2 31.3%, T3 45.5%; P = 0.04). Cystic duct margin status predicted residual disease in the common bile duct (negative cystic duct, 4.3% vs positive
cystic duct, 42.1%) (P = 0.01). Aggressive re-resection for incidental gallbladder carcinoma is warranted as the majority of patients have residual
disease. Although common duct resection does not yield a greater lymph node count, it should be performed at the time of re-resection
for patients with positive cystic duct margins because over one-third will have residual disease in the common bile duct.
Presented at the 48th Annual Meeting of the Society for Surgery of the Alimentary Tract at Digestive Week 2007, Plenary Session,
Washington, DC, March 23, 2007. 相似文献
3.
Summary. Germline mutations of the RET proto-oncogene localized on chromosome 10q11.2 are the underlying cause of hereditary medullary
thyroid carcinoma. In MEN 2A and FMTC, mutations can be found in exons 10, 11, 13 or 14. MEN 2B is characterized by a specific
mutation in exon 16. In a significant number of sporadic MTC somatic mutations in codon 918 (exon 16) are detectable. Some
rare sporadic MTC present somatic mutations in codons 611, 634, 768 and 883. Recently, deletion-insertion of the RET proto-oncogene
in exon 11 and a deletion in exon 10 has been found. RET proto-oncogene mutations are not only responsible for the development
of the familial MTC, but may also play an important role in the pathogenesis of sporadic MTC. However, the prognostic relevance
of these somatic events is still unclear.
相似文献
4.
Zusammenfassung Die verschiedenen Formen des Hyperparathyreoidismus werden überwiegend von Hyperplasien und Adenomen der Nebenschilddrüsen verursacht. Während früher die Diagnose des Pathologen (meist schon im intraoperativen Gefrierschnitt) für das chirurgische Vorgehen maßgebend war, wird das Operationsausmaß heute überwiegend durch die wesentlich verbesserte präoperative Diagnostik bestimmt (bildgebende Verfahren) und durch den nach der Entfernung der vergrößerten Nebenschilddrüse(n) intraoperativ gemessenen Abfall des Parathormons kontrolliert. Nichtsdestotrotz sollte dem Pathologen die morphologische Differenzialdiagnose der Hyperplasie, des Adenoms und Karzinoms der Nebenschilddrüsen geläufig sein.
相似文献
相似文献
5.
A. Frilling W. Höppner C. Eng L. Mulligan F. Raue C. E. Broelsch 《Journal of molecular medicine (Berlin, Germany)》1995,73(5):229-233
Medullary thyroid carcinoma occurs sporadically or as a part of the inherited cancer syndrome multiple endocrine neoplasia (MEN) type 2. The MEN 2 gene has been identified as the RET proto-oncogene on chromosome 10. In MEN 2A, RET mutations are detectable in one of five cysteine codons within exons 10 and 11 and in MEN 2B in codon 918 (exon 16). Direct DNA testing for RET proto-oncogene mutations is the method of first choice in presymptomatic screening of MEN 2 families. Gene carriers should be offered prophylactic thyroidectomy. The process of DNA analysis for RET proto-oncogene mutations is demonstrated in one family with hereditary medullary thyroid carcinoma. RET mutations were detectable in five of the nine family members at risk.Abbreviations
MEN
Multiple endocrine neoplasia
-
MTC
Medullary thyroid carcinoma
-
FMTC
Familial medullary thyroid carcinoma
-
PCR
Polymerase chain reaction
-
C-cells
Calcitonin-producing parafollicular cells 相似文献
6.
Frilling B Schiele R Gitt AK Zahn R Schneider S Glunz HG Gieseler U Jagodzinski E Senges J;Maximal Individual Therapy in Acute Myocardial Infarction Study Group 《American heart journal》2004,148(2):306-311
Background
A meta-analysis of randomized trials has shown a significant reduction of mortality rate in patients receiving aspirin for secondary prevention after acute myocardial infarction (AMI). However, a significant number of patients do not receive aspirin after AMI. Little is known about why aspirin is withheld or the long-term outcome of these patients today.Methods
The Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) registry is a multicenter registry of patients with AMI in Germany.Results
Of 4902 patients, 509 (10%) did not receive aspirin at the time of discharge from the hospital. The mean follow-up period for these patients was 17 months. Relative contraindications to aspirin were significantly associated with the withholding of aspirin (in-hospital bleeding: odds ratio [OR], 3.56; 95% CI, 1.86-6.80; history of peptic ulcer: OR, 2.49; 95% CI, 1.62-3.83). Absolute contraindications to aspirin were rare (2.2%). Other medications of proven benefit were also given less often in these patients (β-blockers: 49.0% vs 61.9%, P <.001; angiotensin-converting enzyme inhibitors: 65.6% vs 70.2%, P = .06; statins: 12.2% vs 15.1%, P = .10). Patients who were not given aspirin were at high risk for vascular events. They were more likely to have a history of prior AMI (OR, 1.34; 95% CI, 1.02-1.79), were in critical clinical condition at admission more often (cardiogenic shock: OR, 1.98; 95% CI, 1.09-3.56; overt heart failure: OR, 1.6; 95% CI, 1.05-2.3), and received acute revascularization less often (OR, 1.32; 95% CI, 1.05-1.67). The 1-year mortality was 2-times higher in patients who did not receive aspirin than in patients who did receive aspirin (16.5% vs 8.3%, P <.001). A significant association of withheld aspirin at discharge with a higher long-term mortality rate was confirmed with multivariate analysis (OR, 1.62; 95% CI, 1.15-2.29).Conclusions
Ten percent of patients who sustained an AMI did not receive aspirin at the time of hospital discharge. Most of these patients were at high risk for cardiovascular events. Withheld aspirin was significantly associated with higher mortality rate during follow up. 相似文献7.
8.
Henning Dralle Thomas J. Musholt Jochen Schabram Thomas Steinmüller Andreja Frilling Dietmar Simon Peter E. Goretzki Bruno Niederle Christian Scheuba Thomas Clerici Michael Hermann Jochen Kußmann Kerstin Lorenz Christoph Nies Peter Schabram Arnold Trupka Andreas Zielke Wolfram Karges Markus Luster Kurt W. Schmid Dirk Vordermark Hans-Joachim Schmoll Reinhard Mühlenberg Otmar Schober Harald Rimmele Andreas Machens 《Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie》2013,398(3):347-375
Introduction
Over the past years, the incidence of thyroid cancer has surged not only in Germany but also in other countries of the Western hemisphere. This surge was first and foremost due to an increase of prognostically favorable (“low risk”) papillary thyroid microcarcinomas, for which limited surgical procedures are often sufficient without loss of oncological benefit. These developments called for an update of the previous practice guideline to detail the surgical treatment options that are available for the various disease entities and tumor stages.Methods
The present German Association of Endocrine Surgeons practice guideline was developed on the basis of clinical evidence considering current national and international treatment recommendations through a formal expert consensus process in collaboration with the German Societies of General and Visceral Surgery, Endocrinology, Nuclear Medicine, Pathology, Radiooncology, Oncological Hematology, and a German thyroid cancer patient support organization.Results
The practice guideline for the surgical management of malignant thyroid tumors includes recommendations regarding preoperative workup; classification of locoregional nodes and terminology of surgical procedures; frequency, clinical, and histopathological features of occult and clinically apparent papillary, follicular, poorly differentiated, undifferentiated, and sporadic and hereditary medullary thyroid cancers, thyroid lymphoma and thyroid metastases from primaries outside the thyroid gland; extent of thyroidectomy; extent of lymph node dissection; aerodigestive tract resection; postoperative follow-up and surgery for recurrence and distant metastases.Conclusion
These evidence-based recommendations for surgical therapy reflect various “treatment corridors” that are best discussed within multidisciplinary teams and the patient considering tumor type, stage, progression, and inherent surgical risk. 相似文献9.
Thomas J. Musholt Thomas Clerici Henning Dralle Andreja Frilling Peter E. Goretzki Michael M. Hermann Jochen Ku?mann Kerstin Lorenz Christoph Nies Jochen Schabram Peter Schabram Christian Scheuba Dietmar Simon Thomas Steinm��ller Arnold W. Trupka Robert A. Wahl Andreas Zielke Andreas Bockisch Wolfram Karges Markus Luster Kurt W. Schmid 《Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie》2011,396(5):639-649
Introduction
Benign thyroid disorders are among the most common diseases in Germany, affecting around 15 million people and leading to more than 100,000 thyroid surgeries per year. Since the first German guidelines for the surgical treatment of benign goiter were published in 1998, abundant new information has become available, significantly shifting surgical strategy towards more radical interventions. Additionally, minimally invasive techniques have been developed and gained wide usage. These circumstances demanded a revision of the guidelines.Methods
Based on a review of relevant recent guidelines from other groups and additional literature, unpublished data, and clinical experience, the German Association of Endocrine Surgeons formulated new recommendations on the surgical treatment of benign thyroid diseases. These guidelines were developed through a formal expert consensus process and in collaboration with the German societies of Nuclear Medicine, Endocrinology, Pathology, and Phoniatrics & Pedaudiology as well as two patient organizations. Consensus was achieved through several moderated conferences of surgical experts and representatives of the collaborating medical societies and patient organizations.Results
The revised guidelines for the surgical treatment of benign thyroid diseases include recommendations regarding the preoperative assessment necessary to determine when surgery is indicated. Recommendations regarding the extent of resection, surgical techniques, and perioperative management are also given in order to optimize patient outcomes.Conclusions
Evidence-based recommendations for the surgical treatment of benign thyroid diseases have been created to aid the surgeon and to support optimal patient care, based on current knowledge. These recommendations comply with the Association of the Scientific Medical Societies in Germany requirements for S2k guidelines. 相似文献10.
Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma 总被引:9,自引:0,他引:9
Frilling A Görges R Tecklenborg K Gassmann P Bockhorn M Clausen M Broelsch CE 《Surgery》2000,128(6):1067-1074
BACKGROUND: Patients with well-differentiated thyroid cancer (WDTC) regularly have an excellent prognosis. However, tumor recurrence either involving the thyroid bed or the regional lymph nodes, or both, can be associated with significant morbidity and even mortality. The aim of the follow-up after primary surgery is to detect recurrent disease at its earliest stage. We assessed the value of different diagnostic methods in detecting locoregional recurrence in patients with WDTC. METHODS: We prospectively identified 150 patients with WDTC. Of those, 43 (28.7%) presented with recurrent disease. Ultrasonography-guided fine needle biopsy (US-FNB), iodine 131 ((131)I) wholebody scintigraphy, thyroglobulin (Tg) measurement, and fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) were carried out. RESULTS: Ultrasonography detected malignant lesions in 95.3% of the patients. The true positive rate of US-FNB was 95.3%. (131)I scanning had true positive, false negative, and false positive results in 54.2%, 40.0%, and 5.7% of the cases, respectively. In 85.7% of the patients, Tg levels were within pathologic range. Among the 13 patients who underwent FDG-PET, 84.6% showed pathologic uptake indicating malignancy. US and US-FNB provided the highest specificity for detecting recurrence (P <.001). CONCLUSIONS: In patients with WDTC and locoregional recurrence, US and US-FNB are the most sensitive methods in detecting local recurrence or regional lymph node metastases. FDG-PET is valuable in case of negative (131)I scanning results and elevated serum Tg levels. The method has limitations in finding minimal disease. 相似文献